- Home
- JLL vs BMRN Comparison
JLL vs BMRN Comparison
Compare JLL & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- BMRN
- Stock Information
- Founded
- JLL 1997
- BMRN 1996
- Country
- JLL United States
- BMRN United States
- Employees
- JLL N/A
- BMRN N/A
- Industry
- JLL Real Estate
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- JLL Finance
- BMRN Health Care
- Exchange
- JLL Nasdaq
- BMRN Nasdaq
- Market Cap
- JLL 13.1B
- BMRN 13.7B
- IPO Year
- JLL 1997
- BMRN 1999
- Fundamental
- Price
- JLL $259.56
- BMRN $71.72
- Analyst Decision
- JLL Strong Buy
- BMRN Buy
- Analyst Count
- JLL 7
- BMRN 22
- Target Price
- JLL $309.00
- BMRN $94.00
- AVG Volume (30 Days)
- JLL 379.3K
- BMRN 1.4M
- Earning Date
- JLL 05-05-2025
- BMRN 04-23-2025
- Dividend Yield
- JLL N/A
- BMRN N/A
- EPS Growth
- JLL 141.97
- BMRN 153.71
- EPS
- JLL 11.30
- BMRN 2.21
- Revenue
- JLL $23,432,900,000.00
- BMRN $2,853,915,000.00
- Revenue This Year
- JLL $11.66
- BMRN $12.23
- Revenue Next Year
- JLL $7.30
- BMRN $9.90
- P/E Ratio
- JLL $23.01
- BMRN $32.42
- Revenue Growth
- JLL 12.87
- BMRN 17.97
- 52 Week Low
- JLL $171.45
- BMRN $60.63
- 52 Week High
- JLL $288.50
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- JLL 50.22
- BMRN 58.67
- Support Level
- JLL $246.90
- BMRN $70.68
- Resistance Level
- JLL $256.38
- BMRN $72.37
- Average True Range (ATR)
- JLL 8.56
- BMRN 1.55
- MACD
- JLL 1.20
- BMRN -0.16
- Stochastic Oscillator
- JLL 68.07
- BMRN 59.92
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.